Supplementary Figures S1 through S4 from Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

Authors:
  • CMCatherine B. Meador
    Catherine B. Meador
  • HJHailing Jin
    Hailing Jin
  • ESElisa de Stanchina
    Elisa de Stanchina
  • CNCaroline A. Nebhan
    Caroline A. Nebhan
  • VPValentina Pirazzoli
    Valentina Pirazzoli
  • LWLu Wang
    Lu Wang
  • PLPengcheng Lu
    Pengcheng Lu
  • HVHuy Vuong
    Huy Vuong
  • KHKatherine E. Hutchinson
    Katherine E. Hutchinson
  • PJPeilin Jia
    Peilin Jia
  • XCXi Chen
    Xi Chen
  • RERosana Eisenberg
    Rosana Eisenberg

Abstract
Fig. S1: Schematic of derivation 'lineages' for drug-sensitive and -resistant cell lines used in this study Fig. S2: Characterization of T790M+ cell lines Fig. S3: Characterization of A+C-resistant cell lines Fig. S4: Characterization of AZD9291-resistant cell lines